We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




MS-Based Immunoassay Detects Levels of Bioactive BNP

By LabMedica International staff writers
Posted on 28 Oct 2008
A novel, quantitative mass spectrometry immunoassay has been developed for the detection of bioactive b-type natriuretic peptide (BNP). More...


A team of scientists discovered very low concentrations of bioactive BNP in plasma obtained from patients with heart failure, and demonstrated direct structural evidence for several proteolytically degraded forms of BNP in these patients.

Intrinsic Bioprobes Inc. (Tempe, AZ, USA) together with colleagues from Scios Inc. (Fremont, CA, USA), Christ Hospital (Cincinnati, OH, USA), and Medivation Inc. (San Francisco, CA, USA) reported their findings in an article that appeared in the October 14, 2008 journal Circulation: Heart Failure.

Commercially available assays for immunoreactive BNP do not reflect the bioactivity of the natriuretic peptide system, since they measure both unprocessed, inactive proBNP and mature BNP 1-32," said Eric Niederkofler, Ph.D., the principal investigator from Intrinsic Bioprobes. BNP is synthesized as a 108 amino acid propeptide and proteolytically processed to release an inactive 76 amino acid N-terminal fragment and bioactive mature BNP 1-32 into the bloodstream.

"This is the first assay capable of detecting and quantifying BNP 1-32 alone. Furthermore, the assay allowed us to study the molecular complexity of BNP degradation, revealing rapid in vitro degradation of BNP 1-32, and necessitating certain preservation protocol during blood collection and subsequent sample handling,” added Dr. Niederkofler.

Intrinsic Bioprobes Inc. is a privately held biotechnology company focused on developing mass spectrometry-based assays and platforms for rapid and sensitive protein biomarker analysis. The company's proprietary technologies consist of Mass Spectrometric Immunoassay (MSIA), a high-performance immunoassay combining micro-scale immunoaffinity capture and mass spectrometry for high throughput analysis of proteins from complex biological matrices, and bioreactive mass spectrometer probes (BRP), devices for rapid, sensitive and accurate protein characterization. These root technologies are incorporated into the MASSAY System, a high-throughput mass spectrometry platform for rapid proteome analysis.

Related Links:
Intrinsic Bioprobes
Scios Inc.
Christ Hospital
Medivation Inc.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.